Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 1;2(2):e188029.
doi: 10.1001/jamanetworkopen.2018.8029.

Estimating Retinal Sensitivity Using Optical Coherence Tomography With Deep-Learning Algorithms in Macular Telangiectasia Type 2

Affiliations

Estimating Retinal Sensitivity Using Optical Coherence Tomography With Deep-Learning Algorithms in Macular Telangiectasia Type 2

Yuka Kihara et al. JAMA Netw Open. .

Abstract

Importance: As currently used, microperimetry is a burdensome clinical testing modality for testing retinal sensitivity requiring long testing times and trained technicians.

Objective: To create a deep-learning network that could directly estimate function from structure de novo to provide an en face high-resolution map of estimated retinal sensitivity.

Design, setting, and participants: A cross-sectional imaging study using data collected between January 1, 2016, and November 30, 2017, from the Natural History Observation and Registry of macular telangiectasia type 2 (MacTel) evaluated 38 participants with confirmed MacTel from 2 centers.

Main outcomes and measures: Mean absolute error of estimated compared with observed retinal sensitivity. Observed retinal sensitivity was obtained with fundus-controlled perimetry (microperimetry). Estimates of retinal sensitivity were made with deep-learning models that learned on superpositions of high-resolution optical coherence tomography (OCT) scans and microperimetry results. Those predictions were used to create high-density en face sensitivity maps of the macula. Training, validation, and test sets were segregated at the patient level.

Results: A total of 2499 microperimetry sensitivities were mapped onto 1708 OCT B-scans from 63 eyes of 38 patients (mean [SD] age, 74.3 [9.7] years; 15 men [39.5%]). The numbers of examples for our algorithm were 67 899 (103 053 after data augmentation) for training, 1695 for validation, and 1212 for testing. Mean absolute error results were 4.51 dB (95% CI, 4.36-4.65 dB) when using linear regression and 3.66 dB (95% CI, 3.53-3.78 dB) when using the LeNet model. Using a 49.9 million-variable deep-learning model, a mean absolute error of 3.36 dB (95% CI, 3.25-3.48 dB) of retinal sensitivity for validation and test was achieved. Correlation showed a high degree of agreement (Pearson correlation r = 0.78). By paired Wilcoxon rank sum test, our model significantly outperformed these 2 baseline models (P < .001).

Conclusions and relevance: High-resolution en face maps of estimated retinal sensitivities were created in eyes with MacTel. The maps were of unequalled resolution compared with microperimetry and were able to correctly delineate functionally healthy and impaired retina. This model may be useful to monitor structural and functional disease progression and has potential as an objective surrogate outcome measure in investigational trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Heeren reported nonfinancial support from Heidelberg Engineering. Dr C. S. Lee received grant support from the Lowy Medical Research Institute, National Eye Institute/National Institute for Health (NEI/NIH), and Research to Prevent Blindness. Dr Tzaridis reported nonfinancial support from the Lowy Medical Research Institute and grants from the German Research Foundation. Dr Holz reported grants, personal fees, and nonfinancial support from Heidelberg Engineering; grants and personal fees from Allergan and Acucela, grants from Alcon, grants from Alimera, and personal fees from Apellis; grants, personal fees, and nonfinancial support from Bayer; grants from CenterVue and Optos; grants and personal fees from Formycon and Genentech/Roche; personal fees from Grayburg Vision; personal fees and nonfinancial support from Geuder; personal fees from Lin BioScience; grants from NightStar X; grants and personal fees from Novartis Pharmaceuticals; personal fees from Pixium Vision, Stealth BioTherapeutics, and Thrombogenics; and grants, personal fees, and nonfinancial support from Zeiss. Dr Charbel Issa reported grant support from the Lowy Medical Research Institute and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Dr Egan reported grants and nonfinancial support from Moorfields NIHR BRC; grants and nonfinancial support from Lowy Medical Research Institute; personal fees from Novartis Pharmaceuticals; and grant support, consultant fees, and honorarium from Heidelberg Engineering. Dr A. Y. Lee has received grant support from Carl Zeiss Meditec, Novartis Pharmaceuticals, Lowy Medical Research Institute, the NEI/NIH, Research to Prevent Blindness, NVIDIA Corporation, and Microsoft Corp; and honorarium from Topcon Corporation. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Deep-Learning Model Structure and Learning Curves
A, Schematic of deep-learning model using a total of 49.9 million variables in 7 convolutional (CN) and 2 fully connected (FC) layers with rectified linear unit (ReLU) activation. The first number after CN refers to the number of filters and the second set of numbers refers to the filter sizes. The number after FC refers to the number of neurons. Stride was set to 1 on all layers. B, Learning curves for training and validation with mean squared error as the loss function. Note that we applied data augmentation to training data, but not to validation data. Max indicates maximum.
Figure 2.
Figure 2.. Comparison of Observed vs Estimated Retinal Sensitivity
A, Scatterplot showing the observed vs estimated retinal sensitivity. B, Bland-Altman plot showing the difference. The solid gray line represents mean difference obtained across the range of values (mean absolute error), whereas the blue dashed lines are the 95% CIs.
Figure 3.
Figure 3.. Microperimetry Results and Predicted High-Resolution Sensitivity Maps
Three patients with MacTel with varying level of disease severity were chosen from the test set (I, II, III). A, The B-scans that crossed the microperimetry stimuli (green line) were chosen. B, The sensitivity scores were overlaid with those B-scans. The color of those overlaid stimuli was manually corrected, resulting in a discrete color scale for each sensitivity score. After deep learning, the model was able to generate a sensitivity estimation line (below optical coherence tomography B-scan), which showed a good correlation with the observed sensitivities. C, Those prediction lines were stitched together to create high-resolution en face sensitivity estimation maps. D, Activation maps of the B-scan, highlighting the regions that the model used for its estimations. Hot areas (red) corresponded to areas most important for the model to estimate normal perimetry values.
Figure 4.
Figure 4.. Estimated Progression of Retinal Sensitivity Loss From Longitudinal Optical Coherence Tomographic Scans in 3 Patients With a Follow-up Time of 12 Months
Patient 1 (A), patient 2 (B), and patient 3 (C).The area of estimated functional loss (red) increased over time, in keeping with a slowly progressive disorder. These high-resolution estimated perimetry maps indicate that the model might be useful for disease monitoring.
Figure 5.
Figure 5.. Comparison With Baseline Estimation Models
Our model was compared against a linear model as well as the LeNet model. Examples from 3 patients are shown from the test set. A, B, and C represent patients with MacTel with varying degrees of starting disease severity and show the en face estimations for the linear model. D, E, and F, The en face estimations for the LeNet model. G, H, and I, The en face estimations for our model. J, Mean absolute error (95% CIs). Our model achieved significantly better results over these baseline models (P < .001, paired Wilcoxon rank sum test).

References

    1. Charbel Issa P, Gillies MC, Chew EY, et al. . Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:-. doi:10.1016/j.preteyeres.2012.11.002 - DOI - PMC - PubMed
    1. Heeren TFC, Clemons T, Scholl HPN, Bird AC, Holz FG, Charbel Issa P. Progression of vision loss in macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2015;56(6):3905-3912. doi:10.1167/iovs.15-16915 - DOI - PubMed
    1. Charbel Issa P, Helb H-M, Rohrschneider K, Holz FG, Scholl HPN. Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2007;48(8):3788-3795. doi:10.1167/iovs.06-1272 - DOI - PubMed
    1. Wong EN, De Soyza JDA, Mackey DA, Constable IJ, Chen FK. Intersession test-retest variability of microperimetry in type 2 macular telangiectasia. Transl Vis Sci Technol. 2017;6(6):1-13. doi:10.1167/tvst.6.6.7 - DOI - PMC - PubMed
    1. Chen FK, Patel PJ, Xing W, et al. . Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci. 2009;50(7):3464-3472. doi:10.1167/iovs.08-2926 - DOI - PubMed

Publication types

LinkOut - more resources